AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14584380 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation
Number of subjects: 167
Study 14584380 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 167
Study 10926377 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 puffs (0.4 mg) via MDI with spacer
Number of subjects: 13
Study 10926377 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 puffs (1.0 mg) via MDI with spacer
Number of subjects: 13
Study 10926377 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg via SVN
Number of subjects: 13
Study 8817987 — intervention group
Group type: EXPERIMENTAL
Intervention: Biventricular bypass (BVB) with oxygenation
Number of subjects: 17
Study 14621850 — intervention group
Group type: EXPERIMENTAL
Intervention: OKT3 (5 mg)
Number of subjects: 0
Study 14621850 — intervention group
Group type: COMPARATOR
Intervention: ATG (dependent on body weight)
Number of subjects: 0
Study 28657810 — intervention group
Group type: EXPERIMENTAL
Intervention: Stand-up paddle practice
Number of subjects: 0
Study 28657810 — intervention group
Group type: COMPARATOR
Intervention: Walking control group
Number of subjects: 0
Study 26671484 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralipid
Number of subjects: 154
Study 26671484 — intervention group
Group type: COMPARATOR
Intervention: IVIG
Number of subjects: 154
Study 26673577 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel 125 mg/m2 plus gemcitabine 1000 mg/m2
Number of subjects: 240
Study 26673577 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel 125 mg/m2 plus carboplatin area under the curve 2 mg×min/mL
Number of subjects: 240
Study 26673577 — intervention group
Group type: COMPARATOR
Intervention: gemcitabine 1000 mg/m2 plus carboplatin area under the curve 2 mg×min/mL
Number of subjects: 240
Study 23780578 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal sympathetic denervation (RDN)
Number of subjects: 346
Study 20958995 — intervention group
Group type: EXPERIMENTAL
Intervention: Hands-on passive stretching treatment procedures directed to the talocrural joint, varying in treatment speed, during the post-acute injury period.
Number of subjects: 0
Study 20958995 — intervention group
Group type: COMPARATOR
Intervention: Hands-on placebo control intervention.
Number of subjects: 0
Study 19934802 — intervention group
Group type: EXPERIMENTAL
Intervention: DC electrical stimulation
Number of subjects: 107
Study 19934802 — intervention group
Group type: COMPARATOR
Intervention: Control (no DC electrical stimulation)
Number of subjects: 107
Study 16968578 — intervention group
Group type: EXPERIMENTAL
Intervention: ALN + D (alendronate 70 mg and cholecalciferol 70 microg)
Number of subjects: 717
Study 16968578 — intervention group
Group type: COMPARATOR
Intervention: ALN (alendronate 70 mg)
Number of subjects: 717
Study 15367828 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (80 mg/day)
Number of subjects: 3000
Study 11388527 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion algorithm group
Number of subjects: 92
Study 11388527 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 92
Study 9241384 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day treatment regimen with sodium artesunate (400 mg on day 1, then 200 mg daily for 4 days, total 1200 mg)
Number of subjects: 91
Study 9241384 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day treatment regimen with sodium artesunate (400 mg on day 1, then 200 mg daily for 6 days, total 1600 mg)
Number of subjects: 91
Study 9241384 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens (5-day and 7-day)
Number of subjects: 91
Study 8493946 — intervention group
Group type: COMPARATOR
Intervention: Conventional disinfection (70% isopropyl pads and povidone iodine saturated swabs)
Number of subjects: 1546
Study 8493946 — intervention group
Group type: EXPERIMENTAL
Intervention: PREP method (70% isopropyl/10% acetone scrub and povidone iodine dispenser)
Number of subjects: 1546
Study 3545368 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneum closed
Number of subjects: 206
Study 3545368 — intervention group
Group type: COMPARATOR
Intervention: Peritoneum left open
Number of subjects: 206
Study 3545368 — intervention group
Group type: COMPARATOR
Intervention: Excluded patients
Number of subjects: 206
Study 28505317 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-curable fluoride varnish (LCFV)
Number of subjects: 22
Study 28505317 — intervention group
Group type: COMPARATOR
Intervention: Conventional fluoride varnish
Number of subjects: 22
Study 27502729 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC → D (epirubicin 75 mg/m², 5-fluorouracil 500 mg/m², cyclophosphamide 500 mg/m² every 2 weeks for 4 cycles, followed by docetaxel 75 mg/m² every 2 weeks for 4 cycles)
Number of subjects: 650
Study 27502729 — intervention group
Group type: COMPARATOR
Intervention: TC (docetaxel 75 mg/m² and cyclophosphamide 600 mg/m² every 21 days for 6 cycles)
Number of subjects: 650
Study 27502729 — intervention group
Group type: COMPARATOR
Intervention: TC
Number of subjects: 650
Study 27502729 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC → D
Number of subjects: 650
Study 27502729 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC → D and TC
Number of subjects: 650
Study 24612304 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyacrylate-based hydrogel (n = 34)
Number of subjects: 75
Study 24612304 — intervention group
Group type: COMPARATOR
Intervention: Amorphous hydrogel (control group, n = 41)
Number of subjects: 75
Study 22895449 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 116
Study 22895449 — intervention group
Group type: COMPARATOR
Intervention: Multifactorial intervention
Number of subjects: 116
Study 22895449 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 116
Study 20814844 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefeeding oral stimulation program (5-min duration)
Number of subjects: 19
Study 20814844 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefeeding oral stimulation program
Number of subjects: 19
Study 19211712 — intervention group
Group type: EXPERIMENTAL
Intervention: 128 mg/d candesartan
Number of subjects: 269
Study 19211712 — intervention group
Group type: COMPARATOR
Intervention: 16 mg/d candesartan
Number of subjects: 269
Study 19211712 — intervention group
Group type: EXPERIMENTAL
Intervention: 64 mg/d candesartan
Number of subjects: 269
Study 15895882 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab + Methotrexate
Number of subjects: 26
Study 15895882 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate alone after stopping infliximab
Number of subjects: 26
Study 12703866 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzyme inhibitors
Number of subjects: 0
Study 10475315 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral transmucosal fentanyl citrate (OTFC) 800 microg
Number of subjects: 133
Study 10475315 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous morphine 10 mg
Number of subjects: 133
Study 10475315 — intervention group
Group type: COMPARATOR
Intervention: Oral transmucosal fentanyl citrate (OTFC) 200 microg
Number of subjects: 133
Study 10475315 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine 2 mg
Number of subjects: 133
Study 10475315 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral transmucosal fentanyl citrate (OTFC) 800 microg and Intravenous morphine 10 mg
Number of subjects: 133
Study 8704237 — intervention group
Group type: EXPERIMENTAL
Intervention: XomaZyme-CD5 Plus
Number of subjects: 243
Study 8704237 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243
Study 1857135 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurses referring patients directly based on positive screening results
Number of subjects: 1328
Study 1857135 — intervention group
Group type: COMPARATOR
Intervention: Standard care by physicians
Number of subjects: 1328
Study 1857135 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients briefly introduced to the alcohol counselor at the time of referral
Number of subjects: 1328
Study 6213382 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 30
Study 6213382 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol plus theophylline
Number of subjects: 30
Study 6213382 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple combination (ipratropium bromide + fenoterol + theophylline)
Number of subjects: 30
Study 6213382 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple combination
Number of subjects: 30
Study 30953836 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingent neurofeedback information from their own brain signals
Number of subjects: 60
Study 30953836 — intervention group
Group type: COMPARATOR
Intervention: Non-contingent neurofeedback information from matched participants
Number of subjects: 60
Study 28437196 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin anti-sepsis intervention
Number of subjects: 787
Study 24936937 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated umbilical cord serum IL-8 and IL-1β levels in infants with low MDI
Number of subjects: 615
Study 24936937 — intervention group
Group type: COMPARATOR
Intervention: Cord serum cytokine levels (IL-8, IL-1β, TNF-α)
Number of subjects: 615
Study 23333168 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate (HA)
Number of subjects: 300
Study 23333168 — intervention group
Group type: COMPARATOR
Intervention: Phosphate-buffered saline (PBS)
Number of subjects: 300
Study 23333168 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate (HA) without concomitant shoulder pathologies
Number of subjects: 300
Study 19819118 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil meal (36% MUFA)
Number of subjects: 0
Study 19819118 — intervention group
Group type: COMPARATOR
Intervention: Walnut meal (16% PUFA, 4% α-linolenic acid)
Number of subjects: 0
Study 19819118 — intervention group
Group type: COMPARATOR
Intervention: Butter meal (35% SFA)
Number of subjects: 0
Study 19864673 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (2 mg of trimethoprim plus 10 mg of sulfamethoxazole per kilogram of body weight) for 12 months
Number of subjects: 576
Study 19864673 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 months
Number of subjects: 576
Study 19864673 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole
Number of subjects: 576
Study 17080491 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible method for extensions of fixed sample or group-sequential trials with t-distributed test statistics
Number of subjects: 0
Study 12743236 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) 400 mg/d
Number of subjects: 62
Study 12743236 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate (VPA) 2,250 mg/d
Number of subjects: 62
Study 12743236 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 11093007 — intervention group
Group type: EXPERIMENTAL
Intervention: rHu‐EPO (200 units/kg every other day)
Number of subjects: 36
Study 11093007 — intervention group
Group type: COMPARATOR
Intervention: Control (no rHu‐EPO)
Number of subjects: 36
Study 11093007 — intervention group
Group type: EXPERIMENTAL
Intervention: rHu‐EPO
Number of subjects: 36
Study 11093007 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-transfusion
Number of subjects: 36
Study 9170385 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthes reconstruction nail
Number of subjects: 18
Study 9170385 — intervention group
Group type: EXPERIMENTAL
Intervention: Zimmer reconstruction nail
Number of subjects: 18
Study 9170385 — intervention group
Group type: EXPERIMENTAL
Intervention: Richards reconstruction nail
Number of subjects: 18
Study 1487624 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritanserin (10 mg)
Number of subjects: 23
Study 1487624 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (0.75 mg)
Number of subjects: 23
Study 1487624 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (10 mg)
Number of subjects: 23
Study 1487624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 2439813 — intervention group
Group type: EXPERIMENTAL
Intervention: Bopindolol
Number of subjects: 22
Study 2439813 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 22
Study 2439813 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 22
Study 2439813 — intervention group
Group type: COMPARATOR
Intervention: Slow-release oxprenolol
Number of subjects: 22
Study 30428601 — intervention group
Group type: EXPERIMENTAL
Intervention: Next generation sequencing (NGS) technology applied to develop SSR markers
Number of subjects: 24
Study 27266868 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led transition intervention consisting of two one-hour individualized sessions focusing on CHD knowledge and self-management skills.
Number of subjects: 120
Study 27266868 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led transition intervention
Number of subjects: 120
Study 24341301 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine 10 mg
Number of subjects: 469
Study 24341301 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg
Number of subjects: 469
Study 24341301 — intervention group
Group type: COMPARATOR
Intervention: Vortioxetine 2.5 mg
Number of subjects: 469
Study 24341301 — intervention group
Group type: COMPARATOR
Intervention: Vortioxetine 5 mg
Number of subjects: 469
Study 24341301 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 469
Study 22561658 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective pulsatile pulmonary perfusion (sPPP)
Number of subjects: 64
Study 22561658 — intervention group
Group type: COMPARATOR
Intervention: Standard CPB
Number of subjects: 64
Study 20713848 — intervention group
Group type: EXPERIMENTAL
Intervention: Four cycles of BEACOPP(baseline) + 20 Gy of IFRT
Number of subjects: 1395
Study 20713848 — intervention group
Group type: EXPERIMENTAL
Intervention: Four cycles of BEACOPP(baseline) + 30 Gy of IFRT
Number of subjects: 1395
Study 20713848 — intervention group
Group type: COMPARATOR
Intervention: Four cycles of ABVD + 20 Gy of IFRT
Number of subjects: 1395
Study 20713848 — intervention group
Group type: COMPARATOR
Intervention: Four cycles of ABVD + 30 Gy of IFRT
Number of subjects: 1395
Study 18621986 — intervention group
Group type: COMPARATOR
Intervention: Saline (Group C)
Number of subjects: 120
Study 18621986 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 75 microg kg(‐1) (Group M)
Number of subjects: 120
Study 18621986 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.5 mg (Group K)
Number of subjects: 120
Study 18621986 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.25 mg + Midazolam 37.5 microg kg(‐1) (Group KM)
Number of subjects: 120
Study 16098435 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil (100 mg by mouth)
Number of subjects: 90
Study 16098435 — intervention group
Group type: COMPARATOR
Intervention: Ibutilide (0.002 mg/kg intravenously)
Number of subjects: 90
Study 16098435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 12453953 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (850 mg b.i.d.)
Number of subjects: 62
Study 12453953 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 10392984 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotypic-resistance testing (n=65)
Number of subjects: 108
Study 9746445 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepine group (clonazepam or alprazolam)
Number of subjects: 13
Study 9746445 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 13
Study 9746445 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepine group
Number of subjects: 13
Study 1667908 — intervention group
Group type: EXPERIMENTAL
Intervention: Papilla preservation flap
Number of subjects: 10
Study 1667908 — intervention group
Group type: COMPARATOR
Intervention: Conventional flap
Number of subjects: 10
Study 1667908 — intervention group
Group type: EXPERIMENTAL
Intervention: Granular hydroxyapatite
Number of subjects: 10
Study 1667908 — intervention group
Group type: COMPARATOR
Intervention: Control group (no granular hydroxyapatite)
Number of subjects: 10
Study 6758474 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented prosthesis
Number of subjects: 112
Study 6758474 — intervention group
Group type: COMPARATOR
Intervention: Non-cemented prosthesis
Number of subjects: 112
Study 31094746 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan (30 mg)
Number of subjects: 20
Study 31094746 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31094746 — intervention group
Group type: COMPARATOR
Intervention: Dextromethorphan and Placebo
Number of subjects: 20
Study 28056945 — intervention group
Group type: EXPERIMENTAL
Intervention: Locally produced lipid-based nutrient supplement (Wawamum) for children 6-23 months, micronutrient powders for children 24-59 months, and wheat soya blends for pregnant and lactating mothers.
Number of subjects: 5000
Study 28056945 — intervention group
Group type: EXPERIMENTAL
Intervention: Food-based interventions delivered by government lady health workers.
Number of subjects: 5000
Study 28056945 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-sectional surveys and community-based cluster randomized controlled trial.
Number of subjects: 5000
Study 26253828 — intervention group
Group type: EXPERIMENTAL
Intervention: NMES (ESG)
Number of subjects: 38
Study 26253828 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 38
Study 24121757 — intervention group
Group type: COMPARATOR
Intervention: TMC310911 (75‐2000 mg)
Number of subjects: 26
Study 24121757 — intervention group
Group type: COMPARATOR
Intervention: TMC310911 (300 mg bid, 600 mg once daily, 150 mg bid plus 100 mg ritonavir bid, 900 mg bid alone, 300 mg bid plus ritonavir 50 mg bid)
Number of subjects: 26
Study 24121757 — intervention group
Group type: EXPERIMENTAL
Intervention: TMC310911 (1200 mg single-dose)
Number of subjects: 26
Study 24121757 — intervention group
Group type: EXPERIMENTAL
Intervention: TMC310911 coadministered with ritonavir
Number of subjects: 26
Study 24121757 — intervention group
Group type: EXPERIMENTAL
Intervention: TMC310911 (up to 2000 mg) and multiple-dose (up to 900 mg)
Number of subjects: 26
Study 24121757 — intervention group
Group type: EXPERIMENTAL
Intervention: TMC310911 with or without ritonavir
Number of subjects: 26
Study 22549597 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal perspective imagery training
Number of subjects: 19
Study 22549597 — intervention group
Group type: EXPERIMENTAL
Intervention: External perspective imagery training
Number of subjects: 19
Study 22549597 — intervention group
Group type: COMPARATOR
Intervention: Relaxation imagery training (Control)
Number of subjects: 19
Study 20518332 — intervention group
Group type: EXPERIMENTAL
Intervention: MCV-A/C
Number of subjects: 0
Study 20518332 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 17961366 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonded filling material
Number of subjects: 115
Study 17961366 — intervention group
Group type: EXPERIMENTAL
Intervention: Unbonded filling material
Number of subjects: 115
Study 15642807 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramosetron 3 microg/kg
Number of subjects: 80
Study 15642807 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramosetron 6 microg/kg
Number of subjects: 80
Study 15642807 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramosetron 12 microg/kg
Number of subjects: 80
Study 15642807 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 12490857 — intervention group
Group type: EXPERIMENTAL
Intervention: MIVAT (Minimally Invasive Video-Assisted Thyroidectomy)
Number of subjects: 33
Study 12490857 — intervention group
Group type: COMPARATOR
Intervention: Conventional near-total thyroidectomy
Number of subjects: 33
Study 9836062 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD group
Number of subjects: 0
Study 9836062 — intervention group
Group type: COMPARATOR
Intervention: Combat control group
Number of subjects: 0
Study 9836062 — intervention group
Group type: COMPARATOR
Intervention: Noncombat control group
Number of subjects: 0
Study 7859961 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen (2 L/minute) via nasal cannula
Number of subjects: 201
Study 7859961 — intervention group
Group type: COMPARATOR
Intervention: Room air
Number of subjects: 201
Study 7859961 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam and meperidine
Number of subjects: 201
Study 2785813 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (0.3 mg)
Number of subjects: 12
Study 2785813 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac (30 mg)
Number of subjects: 12
Study 2785813 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac (50 mg)
Number of subjects: 12
Study 2785813 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7446041 — intervention group
Group type: EXPERIMENTAL
Intervention: High tibial osteotomy with 5 degrees overcorrection of varus deformity
Number of subjects: 78
Study 7446041 — intervention group
Group type: COMPARATOR
Intervention: High tibial osteotomy with normal correction of varus deformity
Number of subjects: 78
Study 31942744 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral nerve block (0.5 mL/kg bupivacaine 0.25% every eight hours)
Number of subjects: 0
Study 31942744 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral nerve block
Number of subjects: 0
Study 31942744 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol (15 mg/kg intravenously every eight hours)
Number of subjects: 0
Study 31942744 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol
Number of subjects: 0
Study 30884335 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy for 10 days
Number of subjects: 15
Study 28299294 — intervention group
Group type: EXPERIMENTAL
Intervention: Chamomile cream (0.5 g applied twice a day for 10 days)
Number of subjects: 114
Study 28299294 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream (applied twice a day for 10 days)
Number of subjects: 114
Study 25209868 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate plus pioglitazone
Number of subjects: 44
Study 25209868 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate alone
Number of subjects: 44
Study 23559220 — intervention group
Group type: EXPERIMENTAL
Intervention: paliperidone ER
Number of subjects: 80